[{"name":"What is the rational for adding anti-angiogenics to Immune Check-Point Inhibitors?","mode":"","is_cme":false,"info":{"presentation":"What is the rational for adding anti-angiogenics to Immune Check-Point Inhibitors?","session":"Session 4","presenter":"S. Peters","photo":null},"playlist":[{"name":"","source":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/lung2019\/9\/v\/9_1c.mp4","source_path":"s3:\/\/eu-cslide-prod-recordings\/lung2019\/9\/v\/9_1c.mp4","cover":"","data":[],"tracks":[],"chapters":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/lung2019\/9\/v\/9_1c.vtt"}]}]{"provider":"CTI","provider_live":0,"type":1,"code":"9L240a02VK"}